Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06657222 · ClinicalTrials.gov registry record · Phase 1

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors and NSCLC, sponsored by Tubulis.

Recruiting
Registry status
Phase 1
Development phase
250
Enrollment target
16
Study locations

NCT06657222 is a Phase 1 study of Advanced Solid Tumors and NSCLC that is actively recruiting participants, run by Tubulis. The registered enrollment target is 250 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (27% higher). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06657222, a Phase 1 study of Advanced Solid Tumors and NSCLC, is actively recruiting participants, sponsored by Tubulis.

RECRUITING
Registry status
Phase 1
Development phase
250 participants
Enrollment target
16
Study locations

Study Summary

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms

Conditions Studied

Advanced Solid Tumors NSCLC HNSCC TNBC - Triple-Negative Breast Cancer CRC SCLC

Interventions

  • DRUG TUB-030

Study Locations (16)

Other

  • Princess Margaret - Toronto
  • Arensia Exploratory Medicine - Bucharest
  • Arensia Exploratory Medicine - Cluj-Napoca
  • Clinica Uni de Navara - Madrid

Texas

  • NEXT Oncology Austin - Austin
  • NEXT Oncology - Dallas - Irving
  • NEXT Oncology - San Antonio - San Antonio

Ohio

  • Cleveland Clinic - Cleveland
  • Ohio State University - Columbus

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • University of Miami - Miami

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-12-13
Est. Completion 2028-12
Phase Phase 1

Sponsor

Tubulis

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06657222

The ClinicalTrials.gov registry entry for NCT06657222 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (27% higher). The listed sponsor is Tubulis, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TUB-030 is the first listed.

NCT06657222 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, Ohio.

Frequently Asked Questions

What is clinical trial NCT06657222 about?

NCT06657222 is a clinical study titled "First in Human Study of TUB-030 in Patients With Advanced Solid Tumors". The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 ...

What is the current status of trial NCT06657222?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-12-13. Estimated completion is 2028-12.

What conditions does trial NCT06657222 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, NSCLC, HNSCC, TNBC - Triple-Negative Breast Cancer, CRC.

What interventions are being tested in trial NCT06657222?

The interventions under investigation include: TUB-030 (DRUG).

Who is sponsoring clinical trial NCT06657222?

This trial is sponsored by Tubulis, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06657222 being conducted?

This trial has 16 study locations across Connecticut, Florida, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

NSCLC

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.